The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Managing patients with R/R DLBCL who are not suitable candidates for autoSCT
In this video, Jennifer Amengual, MD, Columbia University Herbert Irving Comprehensive Cancer Center, New York City, NY, comments on how to identify patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not suitable candidates for autologous stem cell transplantation (autoSCT) and outlines the strategies used to manage these patients. These include CAR T-cell therapy and enrollment into clinical trials investigating novel targeted agents and combination therapies. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
